Innovation Pharmaceuticals Inc (IPIX)

[thefamilyman]

You said, “What would be a reasonable MC once this is proven in clinical trials? Is $5B ($15sh) reasonable?”

Good question. A few years ago Merck bought Cubist for $9.5 billion. Daptomycin (best drug available for ABSSSI) accounted for about 90% of Cubist revenue (~$760 million). At the time, as I recall, Daptomycin only had a couple of years protection left before generics would cut into its revenue. This is relevant because Brilacidin performed as well as Daptomycin in our Phase 2 trial where Daptomycin was used in one arm of the trial as the control. But the big difference was that Brilacidin was given as a single IV dose whereas Daptomycin was given as 7 consecutive days of IV administration. Now think of the other major uses for Brilacidin like oral mucocitis, proctitus, crohns, and of course Covid.